Review of evidence-based support for pretreatment imaging in melanoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 3, 2009, Pages 281-289

  Sabel, Michael S ^a,b   Wong, Sandra L ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chest radiograph; CT scan; Melanoma; PET scan; Radiographic imaging; Sentinel lymph node biopsy; Ultrasound

Indexed keywords

ALGORITHM; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; IMAGE ANALYSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; OCCULT CANCER; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; THORAX RADIOGRAPHY; TREATMENT PLANNING;

EID: 63449129630     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0021     Document Type: Review

References (55)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
2. Coit DG, Andtbacka R, Bichakjian CK, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma, version 2, 2009. Available at: http://www.nccn.org/professionals/physician_gls/fguidelines. asp. Accessed January 12, 2009.
3. Sober AJ, Chuang TY, Duvic M, et al. Guideline of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579-586.
4. Roberts DLL, Anstey AV, Barlow RJ, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2003;146:7-17.
5. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients: monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-157.
6. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703-1705.
7. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004;86:172-178.
8. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135:807-810.
9. Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989;124:847-849.
10. Ardizzoni A, Grimaldi A, Repetto L, et al. Stage I-II melanoma: the value of metastatic work-up. Oncology 1987;44:87-89.
11. Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987;35:163-164.
12. Yancowitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage Tlb-T3b melanoma. Cancer 2007; 110: 1107-1113.
13. Hafner J, Schrrdd MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150:677-686.
14. Wang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004;51:399-405.
15. Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998;134:569-572.
16. Kanzler MH. Initial evaluation of melanoma (letter to the editor). Arch Dermatol 1999;135:1121-1122.
17. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA 1995;274:1703-1705.
18. Webb WR, Gamsu G. Thoracic metastasis in malignant melanoma: a radiographic survey of 66 patients. Chest 1977;71:176-181.
19. Chen JT, Dahmash NS, Ravin CE, et al. Metastatic melanoma to the thorax. AJR Am J Roentgenol 1981;137:293-298.
20. Das Gupta T, Brasfield R. Metastatic melanoma. Cancer 1964; 17:1323-1339.
21. Gross EA. Initial evaluation of melanoma: Don't stop getting that chest x-ray ... yet. Arch Dermatol 1998; 134:623-624.
22. Parish LC, Witkowski JA. Melanoma and the radiograph: sanctity of human life. Lancet 1998; 352:922-923.
23. Klein M, Freedman N, Lotern M, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. Nuklearmedizin 2000;39:56-61.
24. Belhocine T, Pierard G, De Labrassinne M, et al. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002;7:271-278.
25. Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004;14:141-145.
26. Longo MI, Lazaro P, Bueno C, et al. Flourodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003; 29:245-248.
27. Libberecht K, Husada G, Peeters T, et al. Initial staging of malignant melanoma by positron emission tomography and sentinel node biopsy. Acta Chir Belg 2005;105:621-625.
28. Vereecken P, Laporte M, Petein M, et al. Evaluation of extensive intitial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol 2005;19:66-73.
29. Clark PB, Soo V, Kraas J, et al. Futility of flourodeoxyglucose F18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006;141:284-288.
30. Kell MR, Ridge JA, Joseph N, Sigurdson ER. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Onc 2007;33:911-913.
31. Essner R, Belhocine T, Scott AM, Even-Sapir E. Novel imaging techniques in melanoma. Surg Oncol Clin N Am 2006;15:253-283.
32. Ho Shon IA, Chung DK, Saw RP, Thompason JE Imaging in cutaneous melanoma. Nucl Med Commun 2008;29:847-876.
33. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-1494.
34. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 flourodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104:570-579.
35. Alvarez S, Anorbe E, Alcorta P, et al. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006; 186:1342-1348.
36. Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 2003;82:80-84.
37. Voit C, Kron M, Schafer G, et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 2006;13:1682-1689.
38. Starritt EC, Uren RF, Scolyer RA, et al. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:18-23.
39. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638-643.
40. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
41. Strobel K, Skalsky J, Kalff V, et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 2007;34:1366-1375.
42. Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004;139:831-837.
43. Constantinidou A, Hofman M, O'Doherty M, et al. Routine positive emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res 2008;18:56-60.
44. Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance staging in patients with stage III melanoma diagnosed by sentinel lymphadenectomy. J Clin Oncol 2006;24:2858-2865.
45. Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007;14:2133-2140.
46. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252-258.
47. Buzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995;13:2104-2108.
48. Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396-402.
49. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Clinical utility in patients with stage III disease. Cancer 2000;89:1019-1025.
50. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metatatic melanoma. Melanoma Res 1996;6:325-329.
51. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)F flourodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006;13:525-532.
52. Pfannenberg C, Aschoff P, Schanz S, et al. Propspective comparison of (18)F flouroudeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43-557-564.
53. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178-1187.
54. Strobel K, Dummer R, Husarik DB, et al. High risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244:566-574.
55. Harris MT, Berlangieri SU, Cebon JS, et al. Impact of 2-deoxy-2[F-18] fluoro-D-glucose postiron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 2005;7:304-308.